2003
DOI: 10.1046/j.1538-7836.2003.00017.x
|View full text |Cite
|
Sign up to set email alerts
|

Low molecular weight heparins: are they interchangeable? No

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
24
0

Year Published

2004
2004
2019
2019

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 41 publications
(25 citation statements)
references
References 15 publications
1
24
0
Order By: Relevance
“…The statistically significant findings of Hyun et al . showed high levels of sVCAM-1 in patients with operable breast cancer and metastasis [26]. Similar findings, regarding sICAM-1 and sVCAM-1, were found in the cases of patients with stomach cancer in the study by Yoo et al .…”
Section: Discussionsupporting
confidence: 69%
“…The statistically significant findings of Hyun et al . showed high levels of sVCAM-1 in patients with operable breast cancer and metastasis [26]. Similar findings, regarding sICAM-1 and sVCAM-1, were found in the cases of patients with stomach cancer in the study by Yoo et al .…”
Section: Discussionsupporting
confidence: 69%
“…Marine environment is characterized by extreme physicochemical conditions and harbours unusual microbes with potential of different biotechnological applications. Hence, in order to survive in such conditions marine microbes follow some unique biochemical pathways resulting in the production of novel bioactive compounds including, exopolysaccharides [1], [2]. More importantly, marine microbes tend to have significant osmotic tolerance leading to their capability of polysaccharide production at higher sugar concentration, which is very much desired for development of an economically feasible process for polysaccharide production.…”
Section: Introductionmentioning
confidence: 99%
“…Based on their different pharmacological and therapeutic profiles, LMWHs are largely considered by the experts and regulatory agencies such as the US FDA to be distinct drugs requiring indication and dosage specifications for each product. Therapeutic and generic interchanges are not recommended among different LMWHs, as this may compromise medical and surgical patient care [1]. The differences among the LMWHs are due to their molecular and structural properties.…”
mentioning
confidence: 99%
“…Both the biological and pharmacological differences impact on the clinical safety and efficacy of each LMWH. The clinical performance of enoxaparin, dalteparin, and nadroparin has been differentiated in various settings [1,6]. Levels of evidence also exist relating to the variable effects of different LMWHs on specific patient populations, e.g., patients with renal impairment.…”
mentioning
confidence: 99%